Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 5/2014

01-05-2014 | Original Article

Apoptosis and KI 67 index correlate with preoperative chemotherapy efficacy and better predict the survival of gastric cancer patients with combined therapy

Authors: Aiwen Wu, Yongning Jia, Bin Dong, Lei Tang, Yiqiang Liu, Hong Du, Peng Yuan, Peide Dong, Jiafu Ji

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2014

Login to get access

Abstract

Purpose

The correlation of apoptotic and proliferation index with preoperative chemotherapy efficacy was investigated. Their prognostic value was also explored.

Methods

167 patients were enrolled, curative gastrectomy and D2 lymphadenectomy were performed, and a total of 12 cycles of perioperative mFOLFOX7 chemotherapy was recommended. Apoptosis index (AI) and Ki67 index (KI) in surgical specimens were detected.

Results

Apoptosis index, KI and AI/KI were significantly different between patients received perioperative chemotherapy and surgery (CS group, n = 84) and those who received only surgery and postoperative chemotherapy (S group, n = 83). In the CS group, number of patients who received 2, 4, 6 cycles of preoperative chemotherapy were, respectively, 28, 53 and 3. AI, KI and AI/KI were closely related to pathological response. Cutoff value of AI and AI/KI for response separated CS group patients into two subgroups with significant different prognosis and picked up more potential responders than pathological evaluation, especially in pathological response evaluation grade 1a–b.

Conclusions

Apoptosis index, KI and AI/KI are significantly related to chemotherapy efficacy and prognosis of gastric cancer patients who received perioperative chemotherapy and radical gastrectomy. They could be used in combination with pathological response evaluation to distinguish more potential responders.
Appendix
Available only for authorised users
Literature
1.
2.
Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, Participants MT (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355(1):11–20. doi:10.​1056/​NEJMoa055531 PubMedCrossRef
3.
Forones NM, Carvalho AP, Giannotti-Filho O, Lourenco LG, Oshima CT (2005) Cell proliferation and apoptosis in gastric cancer and intestinal metaplasia. Arq Gastroenterol 42(1):30–34PubMedCrossRef
4.
Gokhale S, Rosen D, Sneige N, Diaz LK, Resetkova E, Sahin A, Liu J, Albarracin CT (2007) Assessment of two automated imaging systems in evaluating estrogen receptor status in breast carcinoma. Appl Immunohistochem Mol Morphol 15(4):451–455. doi:10.​1097/​PAI.​0b013e31802ee998​ PubMedCrossRef
5.
Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379(6560):88–91. doi:10.​1038/​379088a0 PubMedCrossRef
6.
7.
Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA (1999) Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 229(3):303–308PubMedCentralPubMedCrossRef
8.
9.
Mofidi R, Walsh R, Ridgway PF, Crotty T, McDermott EW, Keaveny TV, Duffy MJ, Hill AD, O’Higgins N (2003) Objective measurement of breast cancer oestrogen receptor status through digital image analysis. Eur J Surg Oncol 29(1):20–24PubMedCrossRef
10.
11.
O’Connell GJ, Ryan E, Murphy KJ, Prefontaine M (1987) Predictive value of CA 125 for ovarian carcinoma in patients presenting with pelvic masses. Obstet Gynecol 70(6):930–932PubMed
12.
O’Dwyer PJ, Stevenson JP, Johnson SW (2000) Clinical pharmacokinetics and administration of established platinum drugs. Drugs 59(Suppl 4):19–27PubMedCrossRef
13.
Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker K, Buck AK, Dobritz M, Fink U, Ulm K, Schuster T, Schwaiger M, Siewert JR, Krause BJ (2008) Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res 14(7):2012–2018. doi:10.​1158/​1078-0432.​CCR-07-0934 PubMedCrossRef
14.
Trillet-Lenoir V, Chapuis F, Touzet S, Barbier JY, Freyer G, Gaudin JL, Lombard-Bohas C, Valette PJ, Lledo G, Gouttebel MC, Boyer JD, Chassignol L, Hamon H, Claudel-Bonvoisin S, Leprince E, Amoyal P, Glehen O, Darnand P, Heilmann MO, Bleuse JP (2004) Any clinical benefit from the use of oncofoetal markers in the management of chemotherapy for patients with metastatic colorectal carcinomas? Clin Oncol (R Coll Radiol) 16(3):196–203CrossRef
15.
Verlato G, Zanoni A, Tomezzoli A, Minicozzi A, Giacopuzzi S, Di Cosmo M, Franceschetti I, de Manzoni G (2010) Response to induction therapy in oesophageal and cardia carcinoma using Mandard tumour regression grade or size of residual foci. Br J Surg 97(5):719–725. doi:10.​1002/​bjs.​6949 PubMedCrossRef
16.
17.
Metadata
Title
Apoptosis and KI 67 index correlate with preoperative chemotherapy efficacy and better predict the survival of gastric cancer patients with combined therapy
Authors
Aiwen Wu
Yongning Jia
Bin Dong
Lei Tang
Yiqiang Liu
Hong Du
Peng Yuan
Peide Dong
Jiafu Ji
Publication date
01-05-2014
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2014
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-014-2410-3

Other articles of this Issue 5/2014

Cancer Chemotherapy and Pharmacology 5/2014 Go to the issue

Original Article

Pharmacokinetics, placenta, and brain uptake of paclitaxel in pregnant rats

Original Article

A phase I clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicin as first-line treatment in metastatic breast cancer

Original Article

Intravesical mitomycin C combined with local microwave hyperthermia in non-muscle-invasive bladder cancer with increased European Organization for Research and Treatment of Cancer (EORTC) score risk of recurrence and progression

Original Article

A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors

Original Article

Folates provoke cellular efflux and drug resistance of substrates of the multidrug resistance protein 1 (MRP1)

Original Article

The impact of 5-formyltetrahydrofolate on the anti-tumor activity of pralatrexate, as compared to methotrexate, in HeLa cells in vitro
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits